

PE anti-human Podoplanin

Catalog # / Size: 2285015 / 25 tests
2285020 / 100 tests

Clone: NC-08


Isotype: Rat IgG2a, λ

Reactivity: Human

Preparation: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).

Concentration: Lot-specific



Human glioblastoma cell line LN319 stained with NC-08 PE

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. **Test size products are transitioning from 20 microL to 5 microL per test.** Please check your vial or your CoA to find the suggested use of this reagent per million cells in 100 microL staining volume or per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes: Additional reported applications (for the relevant formats) include: immunofluorescence¹.

Application References: 1. Fujino N, *et al.* 2012. *Am. J. Respir. Cell. Mol. Biol.* 46:422. (FC, IF)

Description: Podoplanin is a 40-43 kD type-I transmembrane sialomucin-type glycoprotein, also known as T1a, gp36, gp38, gp40, and Aggrus. Originally detected on the surface of podocytes, further characterization showed podoplanin has a broad tissue distribution, including mesothelial cells, epithelial cells, follicular dendritic cells, and a variety of tumor cells. It has been reported that podoplanin is the ligand of CLEC2 and is involved in lymphatic vessel formation, platelet aggregation, and tumor metastasis. Podoplanin may serve as a useful marker for tumor diagnosis and prognosis.

Antigen References:

1. Raica M, *et al.* 2008. *Anticancer Res.* 28:2997.
2. Xie Q, *et al.* 2008. *Int. J. Clin. Exp. Pathol.* 1:276.
3. Ogasawara S, *et al.* 2008. *Hybridoma.* 27:259.
4. Kato Y, *et al.* 2